Researchers will provide clues about whether Eli Lilly & Co.’s risky bet on an experimental drug for Alzheimer’s disease ultimately pays off—for patients and for Lilly’s bottom line.

Scientists are scheduled to present results from a clinical trial of the drug, solanezumab, at the Alzheimer’s Association International Conference in Washington. The outcomes will help signal whether Lilly’s drug can overcome earlier, negative studies and become the first marketed treatment to slow the worsening of the underlying...